Keywords: sanofi, beats, forecasts, 2nd-qtr, sales, up, sanofi-synthelabo
Sanofi beats forecasts: 2nd-qtr sales up 19.4%
Article | 26 July 2004
Sanofi-Synthelabo turned in a robust performance for the second quarterof 2004, beating expectations with a 19.4% sales increase to 2.27 billion euros ($2.82 billion), ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
